On January 23, 2018, Obalon Therapeutics Inc announced that it was canceling its previously announced public offering after its auditor, KPMG LLP, received a complaint from a "purported whistleblower" alleging "improper revenue recognition" during Q4 2017. Shares of Obalon Therapeutics Inc ...
Delivered by KPMG Today (@KPMG_TO)
Article continues here
Follow @KPMG_TO on Twitter to get latest updates
